RAPID

A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)

What's the purpose of the trial?

This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \
Trial status

Accepting patients

Phase
Phase 1
Enrollment
40
Last Updated
1 week ago

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Cohort -1

Accepting patients

Cohort 1

Accepting patients

Cohort 2

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.